Medicinext Pharma LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medicinext Pharma LLP Pharmaceutical Export Portfolio Dataset — 2 Products, $155.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medicinext Pharma LLP — Pharmaceutical Exporter Profile (2026) | 2 Products, $155.2K Trade | TransData Nexus

Medicinext Pharma LLP

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $155.2K Total Trade · DGFT Verified

Medicinext Pharma LLP is an Indian pharmaceutical exporter with a total trade value of $155.2K across 2 products in 2 therapeutic categories. Based on 25 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Docusate ($140.4K), Vinblastine ($14.7K), .

Medicinext Pharma LLP — Export Portfolio & Destination Treemap

Medicinext Pharma LLP pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medicinext Pharma LLP? — Company Overview & Market Position

Medicinext Pharma LLP is a healthcare-focused limited liability partnership incorporated on February 28, 2020, in Ahmedabad, Gujarat, India. The company operates under the Corporate Identification Number (CIN) AAS-0940 and is registered with the Registrar of Companies (RoC) Ahmedabad. Its registered office is located at 510, 31 Five, B/H Divyabhaskar House Nr. Vodafone House, Corporate Road, Maka Rba, Ahmedabad, Gujarat, 380015.

Medicinext Pharma LLP is a limited liability partnership (LLP) governed by the LLP Act, 2008. The company has a total obligation of contribution of ₹0.10 million as of January 5, 2026. The company's leadership includes Designated Partners Meghaben Vishal Bhatt, Parth Mehta, and Rohit Nagar, who have been associated with the company since May 1, 2021.

What Does Medicinext Pharma LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Docusate$140.4K 2Vinblastine

Product Portfolio — Top 2 by Export Value

Medicinext Pharma LLP exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Docusate	Gastrointestinal	$140.4K	21	1.5%	6
2	Vinblastine	Oncology	$14.7K	4	2.0%	13

Medicinext Pharma LLP exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $155.2K. The top category is Gastrointestinal (90.5% of portfolio), followed by Oncology (9.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Medicinext Pharma LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medicinext Pharma LLP operates manufacturing facilities that adhere to stringent WHO-GMP standards, ensuring compliance with regulations in the USA and EU countries. The company specializes in the production of various pharmaceutical dosage forms, including tablets, capsules, injections, nasal sprays, eye/ear drops, syrups and suspensions, suppositories and pessaries, creams and gels, and effervescent tablets.

3Key Leadership

The key leadership of Medicinext Pharma LLP comprises Designated Partners Meghaben Vishal Bhatt, Parth Mehta, and Rohit Nagar. Meghaben Vishal Bhatt and Parth Mehta have been associated with the company since May 1, 2021. Rohit Nagar has also been a Designated Partner since May 1, 2021.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medicinext Pharma LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medicinext Pharma LLP has established a presence in regulated markets, including the USA and EU, by ensuring that its manufacturing facilities meet stringent WHO-GMP standards. The company focuses on operating in these regulated and stringent regulated markets, exporting finished pharmaceutical formulations and nutraceuticals.

2Emerging Markets

Medicinext Pharma LLP has expanded its reach to emerging markets across Asia, the Commonwealth of Independent States (CIS), Latin America, and Africa. The company operates in over 20 countries in these regions through distribution partners, marketing its own brands. This strategic expansion enables Medicinext to offer its products to a broader global audience.

3Geographic Strategy

Medicinext Pharma LLP's geographic strategy involves diversification across various international markets, including both regulated and emerging regions. By operating in over 20 countries across Asia, CIS, Latin America, and Africa, the company mitigates concentration risk and leverages growth opportunities in diverse markets. This approach aligns with its vision of becoming a "Global Wellbeing Partner."

Medicinext Pharma LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Medicinext Pharma LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company emphasizes compliance with stringent WHO-GMP standards, which are recognized by the FDA. However, without explicit FDA approvals or registrations, the company's products may face challenges in entering the U.S. market.

2WHO & EU GMP

Medicinext Pharma LLP's manufacturing facilities comply with WHO-GMP standards, ensuring that its products meet international quality benchmarks. The company focuses on operating in regulated markets, including the USA and EU, by adhering to these stringent manufacturing practices.

3CDSCO & Indian Regulatory

Medicinext Pharma LLP holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has also obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities. These regulatory compliances enable Medicinext to manufacture and export pharmaceutical products both domestically and internationally.

Medicinext Pharma LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medicinext Pharma LLP operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on regulated markets and its diverse product portfolio position it as a notable competitor. The company's emphasis on quality and compliance with international standards differentiates it from competitors.

2Key Differentiators

Medicinext Pharma LLP's key differentiators include its commitment to quality, as evidenced by adherence to WHO-GMP standards, and its diverse product portfolio encompassing various pharmaceutical dosage forms. The company's strategic focus on both regulated and emerging markets allows it to leverage growth opportunities across different regions. Additionally, Medicinext's emphasis on affordability and accessibility aligns with its vision of becoming a "Global Wellbeing Partner."

3Strategic Position

Medicinext Pharma LLP's current strategic direction involves expanding its presence in both regulated and emerging markets, focusing on the export of finished pharmaceutical formulations and nutraceuticals. The company's future outlook includes further diversification of its product portfolio and geographic reach, aiming to strengthen its position as a global player in the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Medicinext Pharma LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medicinext Pharma LLP has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $155,000 USD across 25 shipments. The company's portfolio concentration, with its top five products accounting for 100% of exports, indicates a focused approach to its product offerings. The company's adherence to WHO-GMP standards and its presence in over 20 countries suggest reliability and consistency in its supply chain operations.

2Certifications to Verify

Importers should verify the following certifications when considering products from Medicinext Pharma LLP:

WHO-GMP Certification: To ensure compliance with international manufacturing standards.

EU GMP Certification: To confirm adherence to European Union manufacturing standards.

ISO Certifications: To assess the company's commitment to quality management systems.

Frequently Asked Questions — Medicinext Pharma LLP

How many pharmaceutical products does Medicinext Pharma LLP export from India?

Medicinext Pharma LLP exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Docusate ($140.4K), Vinblastine ($14.7K). Total export value is $155.2K.

What is Medicinext Pharma LLP's total pharmaceutical export value?

Medicinext Pharma LLP's total pharmaceutical export value is $155.2K, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Medicinext Pharma LLP cover?

Medicinext Pharma LLP exports across 2 therapeutic categories. The largest are Gastrointestinal (90.5%, 1 products), Oncology (9.5%, 1 products).

Get Full Medicinext Pharma LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.